NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 6.74 against a street estimate of 5.68 — a beat of 18.7%.
with an average price target of ₹3,205.00.
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 RPG LIFE SCIENCES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • API business external sales (FY26): ~95.1 Cr INR • InvAscent investment consideratio | 2026-09-02 |
| Investor presentation | 2026-07-28 |
| Annual report FY2026 RPG LIFE SCIENCES LIMITED – FY 2025-26 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹707.52 crores – growth of 8.3% vs FY25 (₹6 | 2026-07-01 |
| Investor presentation · Q4 FY26 RPG LIFE SCIENCES SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • FY26 Revenue: ₹707.5 crores (8.3% growth vs FY25); 5-year CAGR of 12.7% • FY26 EBI | 2026-05-25 |
| Q4 FY26 earnings call | 2026-05-08 |
| Quarterly results · Q4 FY26 RPG LIFE SCIENCES LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations FY2025-26: Rs. 70,752 lakhs (vs Rs. 65,343 lakhs in FY2024- | 2026-05-06 |
| Investor presentation | 2026-04-30 |
| Quarterly results | 2026-02-09 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹24 / share ex-date Jul 9, 2026 | 2026-07-09 |
| Announcement | Date |
|---|---|
| Order received from GST Authority, Gujarat Disclosure under Regulation 30 of SEBI LODR, 2015 for details of order received from GST Authority, Gujarat. | 2025-11-28 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for RPG Life Sciences Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.